Sanofi receives marketing approval for its diabetes drug Soliqua™ in India

Sanofi (India) announced that it has received marketing authorization for its diabetes drug Soliqua™ (in pre-...

March 28, 2023 | Tuesday | Regulatory
Merck KGaA Secures Exclusive Worldwide Rights to BAVENCIO® (avelumab)

Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer Deal is the latest exam...

March 28, 2023 | Tuesday | News
Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer

Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4  combinations have reported only 3-10% re...

March 28, 2023 | Tuesday | News
Incyte's Pemazyre® (pemigatinib) Approved in Japan for Myeloid/Lymphoid Neoplasms (MLNs)

ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...

March 28, 2023 | Tuesday | News
EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab)

HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted...

March 26, 2023 | Sunday | News
CancerVax Universal Cancer Vaccine Being Developed by UCLA

CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that it...

March 18, 2023 | Saturday | News
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which ...

January 24, 2023 | Tuesday | News
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement ha...

January 03, 2023 | Tuesday | News
Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery

While humans and mice generate antibodies that require heavy and light chain pairing to be functional, camels and sharks generate heavy-chain-only antibodi...

January 02, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close